Naldemedine for the Use of Management of Opioid Induced Constipation

By |2020-07-29T08:59:49-07:00July 29th, 2020|Brief Bulletins from the Field|

According to Urits and Viswanath, Opioid medications are fundamental in anesthesia and analgesia and are often used to treat acute and chronic pain. They achieve their desired effects by modulating pain perception in the central nervous system; however, they also act on opioid receptors in the periphery, causing many undesirable [...]

Cassipa Approved by FDA for Opioid Dependence

By |2018-09-12T15:28:07-07:00September 12th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

A new dosage strength of buprenorphine and naloxone sublingual film was approved recently by the Food and Drug Administration. Cassipa sublingual film, made by Teva Pharmaceuticals, is a 16 mg/4 mg dosage of buprenorphine and naloxone for the maintenance treatment of opioid dependence. Buprenorphine and naloxone sublingual film also is [...]

CDC News in Brief — Fentanyl: A Major Culprit in Opioid Overdoses

By |2017-12-28T06:15:10-08:00December 28th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

CDC researchers find > 50% of people in 10 states who died of opioid overdoses during the second half of 2016 tested positive for fentanyl. Researchers examined 5,152 people who died due to opioid overdose in Maine, Massachusetts, Missouri, New Hampshire, New Mexico, Ohio, Oklahoma, Rhode Island, West Virginia, and [...]

BLOG: Treating Addiction Using Genetic Testing As A Guide

By |2017-12-21T13:59:32-08:00December 21st, 2017|Brief Bulletins from the Field, We Know Psychiatry|

Written by Dr. Bruce Kehr Psychiatrists are using genetic testing to determine which prescription medications work best for treating each patient’s particular addiction. For example, doctors can test patients who suffer from alcohol addiction for variants in a gene called the μ-Opioid Receptor (OPRM1), which has been linked to a [...]

New Buprenorphine Formulation Approved for Medication-Assisted Opioid Treatment

By |2017-12-05T10:29:35-08:00December 5th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

The Food and Drug Administration has approved an extended-release, subcutaneous injection formulation of buprenorphine for use in treating moderate to severe opioid use disorder (OUD), the manufacturer of the drug announced recently. The new product, called Sublocade, is a monthly injection intended for use in patients who have already begun [...]

Powerful New Chinese Opioid Intensifies Crisis: Carfentanil linked to at least 700 deaths

By |2021-11-11T17:14:28-08:00February 18th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

Carfentanil, an opioid said to be 100 times more powerful than fentanyl, has been tied to at least 700 deaths in numerous states. Worst hit include Michigan, Florida, and Ohio, according to data compiled by US authorities. Carfentanil was originally intended to sedate large animals, such as elephants, and is [...]

Title

Go to Top